As a privately held company founded and led by
active research scientists, we understand your
needs as a researcher. Like you, we only want to use
products that are specific and deliver reproducible
results. We validate every one of our thousands of
antibodies and research products in-house. If any
product fails to meet our stringent standards, we
won’t sell it. But when one passes, it’s a big deal. For
over 20 years, researchers have trusted CST to help
them achieve experimental success. You can, too.© 2022 Cell Signaling Technology, Inc. Cell Signaling Technology, CST, and XP are trademarks or registered trademarks of Cell Signaling Technology, Inc. 22-BCH-13880-MAROURPROCESS—YOURSUCCESS.
WE’RE CELEBRATING.
A NEW ANTIBODY
FAILED TO FAIL.
The US FDA has granted a Breakthrough Therapy designation to the first anti-TIGIT therapy
for use in NSCLC in combination with PD-L1 blockade. TIGIT expression in paraffin-
embedded non-small cell lung cancer is observed using TIGIT (E5Y1W) XP®Rabbit mAb
#99567.0422Product.indd 322 4/14/22 7:51 AM